Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

TO THE EDITOR: Novel immunotherapies have recently led to a broadened spectrum of therapeutic options in pediatric B-cell precursor acute lymphoblastic leukemia, even in the setting of relapsed/refractory disease. However, antibody therapy for T-cell acute lymphoblastic leukemia (T-ALL) is